SBIR Phase I: Real-Time Allergen Detection Technology for Dietary Proteins Transferred to Human Milk

SBIR 第一阶段：转移到母乳中的膳食蛋白的实时过敏原检测技术

• 批准号: 2321861
• 负责人: Trillitye Paullin
• 金额: $ 27.49万
• 依托单位: FREE TO FEED, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2321861&HistoricalAwards=false
• 关键词: SBIR; Phase; Real; Time; Allergen

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to provide the first test to determine the allergen content of human milk accurately, quickly, and cost-effectively. As much as 25% of infants have reported allergic responses to dietary proteins found in human milk which often results in breast/body feeding termination. Breast/body feeding is incredibly beneficial to health and continuation of nursing is a human health issue. Studies indicate that human milk is superior to hypoallergenic formula, providing natural antibodies to fight illness, lowering the risk of sudden infant death syndrome, and reducing the probability of developing disorders such as diabetes and leukemia. There is currently no at-home, real-time test for milk allergens on the market.This Small Business Innovation Research (SBIR) Phase I project seeks to develop a real-time at-home allergen detection test. This project lays the groundwork for providing the first mechanism to research early and often allergen introduction through human milk when the immune system has been shown to be susceptible to allergy reduction strategies. The company’s patent-pending technology has the potential to provide a tool to identify allergens quickly and cost-effectively, allowing parents to monitor the presence of likely allergen triggers. The test is performed by the user in a real-time, in an at-home setting, which is a significant advantage over existing tests that require samples to be sent to a laboratory for labor and resource-intensive assays. The lateral flow technology provides a rapid and easy-to-read result, allowing the user to quickly determine whether the milk contains specific non-human protein fragments which are also known to elicit allergic responses in some patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛影响/商业潜力是提供首次测试，以准确、快速且经济高效地确定母乳中的过敏原含量（据多达 25% 的婴儿报告）。对母乳中发现的膳食蛋白质的过敏反应通常会导致母乳/身体喂养的终止，母乳/身体喂养对健康非常有益，而继续哺乳是一个人类健康问题，研究表明母乳优于低过敏性配方奶。自然的抗体来对抗疾病，降低婴儿猝死综合症的风险，并降低患糖尿病和白血病等疾病的可能性。目前市场上还没有针对牛奶过敏原的家庭实时检测。这种小型企业创新。研究 (SBIR) 第一阶段项目旨在开发一种实时家庭过敏原检测测试，该项目为提供第一个机制奠定了基础，以便研究当免疫系统已被证明是通过母乳早期且经常引入过敏原。容易过敏该公司正在申请专利的技术有可能提供一种快速且经济有效地识别过敏原的工具，使父母能够实时监测可能的过敏原触发因素。与需要将样品送到实验室进行劳动力和资源密集型检测的现有检测相比，侧向层析技术提供了快速且易于读取的结果，这是一个显着的优势。快速判断是否有奶含有特定的非人类蛋白质片段，已知这些片段也会引起某些患者的过敏反应。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。